Mereo BioPharma Group Plc (MREO) Stock Price, Financials & Summary

Price chart

Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19

Key dataOct 19, 2026

Open$0.31

From 52W high−86.92%

Volume530901.00

Market cap$48.24M

P/E (TTM)—

P/S (TTM)—

Div yield—

Key dataOct 19, 2026

Open

$0.31

From 52W high

−86.92%

Volume

530901.00

Market cap

$48.24M

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−0.6x

P/E (TTM)

—

RSI (14)

45.1

MomentumView details →

1D Return

−0.30%

YTD Return

−25.99%

SummaryUpdated Jun 1, 2026

Mereo BioPharma Group plc (NASDAQ:MREO) is a clinical-stage biopharmaceutical company founded in 2015 and headquartered in London, United Kingdom. The company went public on NASDAQ in April 2019. Mereo focuses on developing innovative therapeutics for oncology and rare diseases, with a pipeline of antibody-based treatments and small molecule drugs currently in various phases of clinical trials. As a development-stage company, Mereo does not yet generate product revenue and is funded through equity financing while advancing its therapeutic candidates through regulatory approval processes.

Ask drillr about Mereo BioPharma Group Plc →

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

−0.6x

EV/Sales

—

P/S (TTM)

—

P/B (TTM)

1.7x

ProfitabilityView details →

Gross Margin

—

Net Margin

—

EBITDA Margin

—

ROE (TTM)

−97.99%

ROA (TTM)

−80.88%

Asset Turnover

0.00x

GrowthView details →

Revenue YoY

−100.00%

EPS YoY

+42.59%

FCF YoY

+23.74%

Revenue CAGR 3Y

−77.64%

EPS CAGR 3Y

—

EBITDA YoY

+31.81%

MomentumView details →

1D Return

−0.30%

YTD Return

−25.99%

1Y Return

−86.23%

RSI (14)

45.1

vs 50D SMA

+0.11%

vs 200D SMA

−10.16%

Capital & dividendView details →

Debt/Equity

0.04x

Current Ratio

5.88x

Quick Ratio

5.88x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−$0.01

EPS Surprise

0.00%

Beats (12Q)

2/12

Next Q EPS Est

−$0.02

Avg Surprise (4Q)

−25.00%

Rev Surprise

—

Financials snapshotView financials →

Revenue (TTM)

0.00

Net Income (TTM)

−28.08M

Op. CF (TTM)

−25.35M

Next earningsNov 9, 2026 →

Latest newsMore news →

Mereo BioPharma Group plc reported its Q2 2026 financial results, with zero revenue, a net loss of $7.005 million, and diluted EPS of -$0.01, while holding approximately $30 million in cash and cash equivalents as of June 30, 2026.70d ago

Similar companies

MiNK Therapeutics, Inc.INKT iBio, Inc.IBIO LeonaBio, Inc.LONA Clene Inc.CLNN Tevogen Bio Holdings Inc.TVGN Werewolf Therapeutics, Inc.HOWL Find similar companies →

Latest newsMore news →

Mereo BioPharma Group plc received a notice from NASDAQ on 2026-08-18 indicating non-compliance with the minimum bid price requirement under Rule 5550(a)(2), with a compliance deadline of 2027-02-16.62d ago Mereo BioPharma Group plc reported its Q2 2026 financial results, with zero revenue, a net loss of $7.005 million, and diluted EPS of -$0.01, while holding approximately $30 million in cash and cash equivalents as of June 30, 2026.70d ago